In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) reported that Flynn James E has picked up 2,238,587 of common stock as of 2017-07-17.
The acquisition brings the aggregate amount owned by Flynn James E to a total of 2,238,587 representing a 9.98% in the company.
For those not familiar with the company, Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
A glance at Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)’s key stats reveals a current market capitalization of 32.73 Million based on 44.42 Million shares outstanding and a price at last close of $1.45 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2015-11-06, Cashman picked up 3,561 at a purchase price of $5.61. This brings their total holding to 116,085 as of the date of the filing.
On the sell side, the most recent transaction saw Mehra unload 12,528 shares at a sale price of $1.39. This brings their total holding to 15,470.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) as things move forward to see if its progress aligns with these transactions.Subscribe below and we’ll keep you on top of what’s happening before it moves markets.